Abilities of Renewable Changes of Pancreatic Ultrastructure on the Background of Medical Correction of Experimental Diabetes Mellitus


pancreatic islets

How to Cite

Ivantsiv, O. R. (2015). Abilities of Renewable Changes of Pancreatic Ultrastructure on the Background of Medical Correction of Experimental Diabetes Mellitus. Galician Medical Journal, 22(3), 141-145. Retrieved from https://ifnmujournal.com/gmj/article/view/360


Ultrastructural and submicroscopic changes in the pancreas on the background of experimental diabetes mellitus (EDM) correction by exenatide were studied. Diabetes mellitus was modeled by a single intraperitoneal streptozotocin administration. The animals with the level of blood glucose 12-16 mmol/l were taken for the experiment. From the 14th day of the experiment the animals were injected exenatide daily. The histological preparations were stained with haematoxylin-eosin, according to Mallory in our modification [4]. Electronic-microscopic and biochemical methods of study were used. The volumetric share of islets in the pancreas, the part of the area occupied by insulocytes and glucagonocytes in the islets were determined. During the development of EDM the decrease of the area occupied by insulocytes, and the reduction of the area of the islet were observed. On the background of daily administration of exenatide the positive dynamics of insulocytes’ area recovery, the appearance of some “ductal” insulocytes were noted, reorganization of cellular elements of pancreatic islet was observed: reduction of insulocytes’ hypertrophy, some endocrinocytes with no signs of damage, reduction of lymphocytic infiltration of the pancreatic parenchyma. Submicroscopically against the background of medical correction the stabilization of mitochondrial membranes and crests, reduction of kariopknotic nuclei of В-cells were noted. Thus, the results of the study indicate the exenatide ability to stimulate the regeneration of islets of Langerhans.




Antsiferov M., Koteshkova O., Sitnikov V. Correction of metabolic violations in type 2 diabetes mellitus in combination with obesity against the background of exenatide therapy. Vrach. 2009; 5: 29–33.

Ivashchuk S.I., Silko V.P., Kurikeru M.A. Method of morphometric study of the pancreatic parts. Klinichna anatomiia ta operatyvna khirurhiia. 2013; 12:4: 95–97.

Kaidashev I. P. Autoimmune injuries of pancreatic islets in diabetes mellitus. Klinichna imunolohiia, alerholohiia, infektolohiia. 2013; 1:12–15.

Ivantsiv O.R., Bahriy M.M., Popadynets O.H., Popovych Yu.I. Patent 99053, Ukraine, IPC G 01 N 33/00. Method of histological identification of the smooth myocytes’ vascular walls by modification of staining according to Mallory.; patent owner Ivano-Frankivsk National Medical University. № u 2014 14221; appl. 31.12.2014; publ. 05.12.2015, Bull. № 9.

Snigur G.L., Spasov A.A., Voronkova M.P. Peculiarities of the development of endocrinocytes’ apoptosis of islets of Langerhans in experimental diabetes mellitus. Morfologiya. 2010; 137: 4: 175.

Tronko N.D. Achievements of regenerative medicine in type 1 diabetes mellitus therapy. 1. Sources of beta cells obtaining. Endokrinologiya. 2012; 137(1): 74–84.

Barnett A.H., Burger J., Johns D. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007; 29:11: 2333–2348.

Buse J.B., Henry R.R., Han J. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 1 diabetes Diabetes Care. Diabetologia. 27: 2628–2635.

Kim B.M., Ham Y.M., Shin Y.J Clustern expression during regeneration of pancreatic islet β-cell in streptosotozin-induced diabetic rats. Diabetologia. 2001; 44:12: 2192–2202.

Trucco M. Regeneration of the pancreatic β-cell. J.Clin. Invest. 2005; 115:1:5–12.

Viswanathan P., Chaudhuri A., Bhatia R. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr. Pract. 2007; 13:5: 444–450.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.